The role of intracavitary therapies in the treatment of malignant pleural mesothelioma
| Autor: | Alfredo Mussi, Vittorio Aprile, Marco Lucchi, Pietro Bertoglio, Marcello Carlo Ambrogi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.medical_treatment Intracavitary therapy Malignant pleural mesothelioma (MPM) Multimodality treatment Surgery Photodynamic therapy Review Article 030204 cardiovascular system & hematology Complete resection law.invention Resection 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Mesothelioma Pleural mesothelioma business.industry Multimodality Treatment medicine.disease Chemotherapy Drugs 030220 oncology & carcinogenesis Radiology business |
| Popis: | Surgery is one of the steps of multimodality approach for the treatment of MPM. Due to anatomical features, microscopically radical (R0) resection is never possible and a Macroscopic Complete Resection (R1) is considered the target for mesothelioma surgeons. Recently, intracavitary therapies have been described with the aim of extending the loco-regional effect of surgery. Different agents might be administered intrapleurally: chemotherapy drugs are the most widely used, but also photodynamic therapy (PDT) showed to lead to satisfactory long-term outcomes; furthermore, immunotherapies and gene therapies have been also reported. Despite promising results, no high-quality evidences are currently available and controlled randomized trials are required to establish the exact role of intracavitary therapies and to standardize the technique. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|